Avacta ने इक्विटी फंडरेज के लिए ट्रेडिंग रोकी
- Investing.com
तुलना करने के लिए मीट्रिक्स | AVCT | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधAVCTपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −8.8x | −4.8x | −0.3x | |
PEG अनुपात | −0.19 | −0.06 | 0.00 | |
क़ीमत/बुक | 89.5x | 4.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 2,986.4x | 6.8x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 30.9% | 168.4% | 58.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | −4.6% | 8.4% | अनलॉक करें |
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.